LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

Rhea-AI Summary

LENZ Therapeutics (NASDAQ: LENZ), a pre-commercial stage biopharmaceutical company developing aceclidine-based eye drops for presbyopia, announced its participation in the BofA Securities 2025 Health Care Conference. The company's management will engage in a fireside chat and one-on-one meetings at the conference, scheduled for May 13-15, 2025 in Las Vegas.

The presentation will take place on Tuesday, May 13, 2025, at 9:20am PDT / 12:20pm EDT at the Encore Hotel. A live audio webcast will be available on LENZ's website, with a replay accessible for 12 months following the event.

News Market Reaction – LENZ

-2.12%

1 alert

-2.12% News Effect

On the day this news was published, LENZ declined 2.12%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in a fireside chat and one-on-one meetings at the BofA Securities 2025 Health Care Conference taking place May 13- 15, 2025 in Las Vegas, NV.

Details of the event are as follows:
Date: Tuesday, May 13, 2025
Location: Encore Hotel, Las Vegas, Nevada
Time: 9:20am PDT / 12:20pm EDT

A live audio webcast of the BofA Securities 2025 Health Care Conference presentation will be available here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 12 months following the event.

About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.

Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com

FAQ

When is LENZ Therapeutics presenting at the BofA Securities 2025 Health Care Conference?

LENZ Therapeutics is presenting on Tuesday, May 13, 2025, at 9:20am PDT / 12:20pm EDT at the Encore Hotel in Las Vegas.

What is LENZ Therapeutics (NASDAQ: LENZ) developing?

LENZ Therapeutics is developing the first and only aceclidine-based eye drop to improve near vision in people with presbyopia.

Where can I watch LENZ Therapeutics' BofA Securities conference presentation?

The presentation will be available via live audio webcast on LENZ Therapeutics' website (www.LENZ-tx.com) in the Investors & Media section, with a replay available for 12 months.

What type of company is LENZ Therapeutics (LENZ)?

LENZ Therapeutics is a pre-commercial stage biopharmaceutical company focused on developing treatments for presbyopia.